{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:43:01Z","timestamp":1760060581406,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The benefit of adjunctive aminoglycosides in the treatment of patients with febrile neutropenia (FN) is controversial. We investigated the incidence of acute kidney injury (AKI) in patients with FN or suspected infection according to empirical amikacin treatment. Methods: This two-centre, retrospective cohort study was conducted at the University Hospitals of Basel (amikacin group) and Bern (non-amikacin group), Switzerland, between 2016 and 2022. Adult patients requiring antibiotic treatment after autologous hematopoietic stem cell transplantation (HSCT) were included. All patients received empiric beta-lactam treatment combined with amikacin in the amikacin group (only University Hospital Basel). The primary endpoint was the incidence of AKI within seven days after the initiation of antibiotic treatment. Results: Overall, 250 patients were included. The majority was male (n = 163, 65.2%) and had a median age of 61 years (interquartile range (IQR) 55 to 67). The median baseline eGFR was similar in both groups (&gt;90 mL\/min\/1.7 m2). There was no statistically significant difference in the incidence of AKI (4\/125 vs. 5\/125, p = 1.0). The maximum decline in eGFR from baseline within 7 days was significantly higher in the amikacin group (\u22124 mL\/min\/1.7 m2 (IQR 8 to \u221212) vs. \u22122 mL\/min\/1.7 m2 (IQR \u22127 to \u22121), p = 0.001). Two patients suffered from an infection with an extended spectrum beta-lactamase producing (ESBL) pathogen. Conclusions: Amikacin treatment did not significantly impact the incidence of AKI in patients undergoing autologous HSCT. The short-term administration of amikacin in patients with normal to high baseline eGFR is safe regarding renal function. However, in a low-resistance setting, the omission of empirical amikacin treatment should be considered.<\/jats:p>","DOI":"10.3390\/antibiotics14090919","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:10:46Z","timestamp":1757603446000},"page":"919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Sophie","family":"Sch\u00fcrch","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-7404","authenticated-orcid":false,"given":"Sarah","family":"Dr\u00e4ger","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severin","family":"Bausch","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"G\u00fcrtler","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-912X","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hirzel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-1425","authenticated-orcid":false,"given":"Stefano","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parham","family":"Sendi","sequence":"additional","affiliation":[{"name":"Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-957X","authenticated-orcid":false,"given":"Michael","family":"Osthoff","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, 4031 Basel, Switzerland"},{"name":"Department of Internal Medicine, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1702503","article-title":"Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies","volume":"26","author":"Celebi","year":"2000","journal-title":"Bone Marrow Transpl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e13225","DOI":"10.1111\/tid.13225","article-title":"Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on levofloxacin prophylaxis","volume":"22","author":"Signorelli","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Pizzo","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1445-5994.2010.02340.x","article-title":"Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Tam","year":"2011","journal-title":"Intern. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.40.5.1108","article-title":"Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto Infection Program","volume":"40","author":"Cometta","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkf087","article-title":"Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: Results of an open, randomized, multicentre trial","volume":"50","author":"Sanz","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:19:3:161","article-title":"Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia","volume":"19","author":"Montalar","year":"2002","journal-title":"Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1469-0691.2005.01297.x","article-title":"Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients","volume":"12","author":"Viscoli","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.cmi.2017.03.020","article-title":"Secular trends of bloodstream infections during neutropenia in 15,181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS)","volume":"23","author":"Weisser","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0004521","DOI":"10.1128\/AAC.00045-21","article-title":"Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: A Propensity-Matched Cohort Study (AMINOLACTAM Study)","volume":"65","author":"Gudiol","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2165\/00003495-199447060-00004","article-title":"Parenteral aminoglycoside therapy: Selection, administration and monitoring","volume":"47","author":"Kumana","year":"1994","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/j.1552-4604.1991.tb03700.x","article-title":"Amikacin pharmacokinetics: Wide interpatient variation in 98 patients","volume":"31","author":"Zaske","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/infdis\/153.6.1062","article-title":"A model for predicting nephrotoxicity in patients treated with aminoglycosides","volume":"153","author":"Sawyers","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.36.3.679","article-title":"Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia","volume":"36","author":"Etzel","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Bertino","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Giske, C.G., Amara, M., Cant\u00f3n, R., Das, S., Holzknecht, B., Kahlmeter, G., Lindemann, P.C., MacGowan, A., Meletiadis, J., and Muller, A.E. (2025). Aminoglycoside breakpoints\u2013the EUCAST approach and what this means for the clinician. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., 23.","DOI":"10.1016\/j.cmi.2025.08.015"},{"key":"ref_19","first-page":"CD003038","article-title":"Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia","volume":"3","author":"Paul","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_20","first-page":"401","article-title":"Aminoglycoside nephrotoxicity: Do time and frequency of administration matter?","volume":"7","author":"Beauchamp","year":"2001","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1525-1497.1998.00224.x","article-title":"Risk factors for toxicity in elderly patients given aminoglycosides once daily","volume":"13","author":"Paterson","year":"1998","journal-title":"J. Gen. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1086\/383046","article-title":"Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia","volume":"39","author":"Tamura","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000045561","article-title":"Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation","volume":"84","author":"Uppenkamp","year":"2000","journal-title":"Nephron"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40620-023-01809-3","article-title":"Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: A cohort study","volume":"37","author":"Rodrigues","year":"2024","journal-title":"J. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2183044","DOI":"10.1080\/0886022X.2023.2183044","article-title":"Acute kidney injury in autologous hematopoietic stem cell transplant for patients with lymphoma\u2013KDIGO classification with creatinine and urinary output criteria: A cohort analysis","volume":"45","author":"Rodrigues","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_26","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e14123","DOI":"10.1111\/tid.14123","article-title":"Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients","volume":"25","author":"Jandial","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_28","unstructured":"Anresis.ch (2025, January 22). Resistenzdaten Humanmedizin. Available online: https:\/\/www.anresis.ch\/de\/antibiotikaresistenz\/resistance-data-human-medicine\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10096-018-3376-6","article-title":"The effect of short-course gentamicin therapy on kidney function in patients with bacteraemia-a retrospective cohort study","volume":"37","author":"Carlsen","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O\u2019Neal, L., McLeod, L., Delacqua, G., Delacqua, F., and Kirby, J. (2019). The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform., 95.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_34","unstructured":"Sanford (2024, December 01). Body Mass Index (BMI), Body Surface Area (BSA), Ideal Body Weight (IBW), and Lean Body Weight (LBW). Available online: https:\/\/web.sanfordguide.com\/en\/comparisons-1\/calculators\/sg-one-calculators-bmi."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/919\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:44:12Z","timestamp":1760035452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antibiotics14090919"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14090919","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}